Cara Therapeutics (CARA) To See $180M in 2024 Revenue from Korsuva - Needham & Company
Tweet Send to a Friend
Needham & Company analyst Joseph Stringer reiterated a Buy rating and $26.00 price target on Cara Therapeutics (NASDAQ: CARA) after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE